4//SEC Filing
RENTON HOLLINGS 4
Accession 0001415889-25-019242
CIK 0001370053other
Filed
Jul 2, 8:00 PM ET
Accepted
Jul 3, 1:34 PM ET
Size
11.7 KB
Accession
0001415889-25-019242
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
RENTON HOLLINGS
Director
Transactions
- Sale
Common Stock
2025-07-02$23.82/sh−13,675$325,782→ 4,965 total - Exercise/Conversion
Common Stock
2025-07-02$6.93/sh+20,925$145,010→ 25,890 total - Sale
Common Stock
2025-07-02$23.09/sh−7,250$167,408→ 18,640 total - Exercise/Conversion
Common Stock
2025-07-02−20,925→ 0 totalExercise: $6.93Exp: 2025-07-05→ Common Stock (20,925 underlying)
Footnotes (5)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of July 5, 2025.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.425 to $23.395 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.56 to $24.015 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025.
- [F5]In addition to the remaining options to purchase 20,925 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 112,051 shares of common stock, which options vest according to their terms.
Documents
Issuer
ANAPTYSBIO, INC
CIK 0001370053
Entity typeother
Related Parties
1- filerCIK 0001187333
Filing Metadata
- Form type
- 4
- Filed
- Jul 2, 8:00 PM ET
- Accepted
- Jul 3, 1:34 PM ET
- Size
- 11.7 KB